FDA ANDA · ANDA217103
DEFLAZACORT
Sponsor: TEVA PHARMS INC
What this page does not claim
A drug page is a reference view of public FDA data (Drugs@FDA), reproduced as published. SPEQ is not affiliated with the FDA, adds no interpretation to the record, and nothing here is medical, legal, or regulatory advice.
APPLICATION
ANDA217103
TYPE
ANDA
ORIGINAL APPROVAL
2026-10-19
LATEST ACTION
2026-10-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
DEFLAZACORTPrescription
DEFLAZACORT 30MG · TABLET · ORAL
DEFLAZACORTPrescription
DEFLAZACORT 6MG · TABLET · ORAL
DEFLAZACORTPrescription
DEFLAZACORT 36MG · TABLET · ORAL
DEFLAZACORTPrescription
DEFLAZACORT 18MG · TABLET · ORAL
Approval history
2026-10-19UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. Browse every approval SPEQ tracks →